Robert A. Copeland, PhD, founded Accent Therapeutics in September 2017 and serves as its President and Chief Scientific Officer. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology in the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. He has contributed to drug discovery and development efforts leading to 19 investigational new drugs entering human clinical trials. These include the cancer drugs Tazverik™ (tazemetostat), Tafinlar™ (dabrafenib) and Mekinist™ (trametinib), the anemia drug Jesduvroq™ (daprodustat) and the antibiotic Altabax™ (retapamulin). Robert has contributed more than 200 publications to the scientific literature, holds 14 issued US patents and has authored six books in the areas of protein science and enzymology. He is a member of the editorial boards of Molecular Cancer Therapeutics (AACR) and ACS Medicinal Chemistry Letters. He also serves on multiple biotechnology scientific advisory boards. Robert received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Research Fellow at the California Institute of Technology. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) and of the Royal Society of Chemistry.